KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

Authors :: Karen Velastegui
C Cornelius
Pasi A. Jänne
Thian Kheoh
Rebecca S. Heist
Igor I. Rybkin
G J Riely
Melissa Lynne Johnson
Lyudmilla Bazhenova
James G. Christensen
Minal A. Barve
T A Leal
Alexander I. Spira
S-H.I. Ou
Richard C. Chao
Peter D. Olson
Joshua K. Sabari
Jose M. Pacheco
Kyriakos P. Papadopoulos
Source :: European Journal of Cancer. 138:S1-S2
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Cancer Research
Oncology
business.industry
Mutation (genetic algorithm)
Cancer research
Medicine
non-small cell lung cancer (NSCLC)
KRAS
business
medicine.disease_cause
medicine.disease

Full Text Access

Tools